85 related articles for article (PubMed ID: 23076779)
1. Serum protein levels following surgery in breast cancer patients: a protein microarray approach.
Perez-Rivas LG; Jerez JM; Fernandez-De Sousa CE; de Luque V; Quero C; Pajares B; Franco L; Sanchez-Muñoz A; Ribelles N; Alba E
Int J Oncol; 2012 Dec; 41(6):2200-6. PubMed ID: 23076779
[TBL] [Abstract][Full Text] [Related]
2. Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients.
El Agouza IM; Eissa SS; El Houseini MM; El-Nashar DE; Abd El Hameed OM
Angiogenesis; 2011 Sep; 14(3):321-30. PubMed ID: 21553281
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients.
Ahmed HH; Metwally FM; Mahdy ES; Shosha WG; Ramadan SS
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):958-65. PubMed ID: 22953646
[TBL] [Abstract][Full Text] [Related]
6. Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer.
Aharinejad S; Salama M; Paulus P; Zins K; Berger A; Singer CF
Endocr Relat Cancer; 2013 Dec; 20(6):777-83. PubMed ID: 24016870
[TBL] [Abstract][Full Text] [Related]
7. Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer.
Hautmann S; Huland E; Grupp C; Haese A; Huland H
Anticancer Res; 2000; 20(3B):2151-4. PubMed ID: 10928169
[TBL] [Abstract][Full Text] [Related]
8. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
9. [Application of serum proteomic mass spectrum analysis in breast cancer].
Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
[TBL] [Abstract][Full Text] [Related]
10. Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.
Böhm D; Keller K; Wehrwein N; Lebrecht A; Schmidt M; Kölbl H; Grus FH
Oncol Rep; 2011 Nov; 26(5):1051-6. PubMed ID: 21837365
[TBL] [Abstract][Full Text] [Related]
11. [Proteome analysis for identification of tumor-associated biomarkers in breast cancer].
Wang X; Liang WJ; Zhu ZY; Yang MT; Zeng YX
Ai Zheng; 2004 Nov; 23(11 Suppl):1577-81. PubMed ID: 15566683
[TBL] [Abstract][Full Text] [Related]
12. A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer.
Fry SA; Sinclair J; Timms JF; Leathem AJ; Dwek MV
Cancer Lett; 2013 Jan; 328(2):335-44. PubMed ID: 23079531
[TBL] [Abstract][Full Text] [Related]
13. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
14. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
15. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
Lowery AJ; Sweeney KJ; Molloy AP; Hennessy E; Curran C; Kerin MJ
BMC Cancer; 2008 Sep; 8():279. PubMed ID: 18826631
[TBL] [Abstract][Full Text] [Related]
16. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.
Kuerer HM; Thompson PA; Krishnamurthy S; Fritsche HA; Marcy SM; Babiera GV; Singletary SE; Cristofanilli M; Sneige N; Hunt KK
Clin Cancer Res; 2003 Feb; 9(2):601-5. PubMed ID: 12576424
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of calcium-binding protein S100A9 in breast cancer].
Du XM; Chang H; Sun HY; Zhang JY; Gao Y; Shen B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Jun; 28(6):637-9. PubMed ID: 22691358
[TBL] [Abstract][Full Text] [Related]
18. The hTERT mRNA in plasma samples of early breast cancer patients, non-cancer patients and healthy individuals.
Perhavec A; Cerkovnik P; Novakovic S; Zgajnar J
Neoplasma; 2008; 55(6):549-54. PubMed ID: 18999886
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of hepatocyte growth factor in breast cancer patients.
Taniguchi T; Toi M; Inada K; Imazawa T; Yamamoto Y; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):1031-4. PubMed ID: 9816076
[TBL] [Abstract][Full Text] [Related]
20. Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS.
Lei L; Wang XJ; Zheng ZG; Huang J; Cao WM; Chen ZH; Shao XY; Cai JF; Ye WW; Lu HY
Anat Rec (Hoboken); 2011 Jun; 294(6):941-4. PubMed ID: 21548109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
